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To evaluate the c-kit expression in breast cancer, 217 invasive ductal carcinomas of the breast were immunohistochemically stained
for c-kit protein. The c-kit expression was positive in 59 (27%) of 217 tumours, while the c-kit expression was negative in 158 (73%)
of 217 tumours. There was a significant correlation between a negative expression of the c-kit protein and lymph node metastasis
(Po0.0001), and the incidence of a negative expression of the c-kit protein increased as the number of the metastatic lymph nodes
increased (P¼0.0003). The c-kit expression did not significantly correlate with the tumour size, nuclear grade, oestrogen receptor
status, MIB-1 counts and p53 protein expression. A univariate analysis indicated the patients with the negative c-kit expression to
have a worse disease-free survival (DFS) than those with the positive c-kit expression (P¼0.0041), while a multivariate analysis
determined lymph node metastases and the MIB-1 counts to be independently significant factors for DFS. In conclusion, a loss of the
c-kit expression was found in about three-fourth of invasive ductal carcinoma of the breast and was associated with lymph node
metastases. The prognostic implications of the c-kit expression seem to be due to fact that a loss of the c-kit expression is associated
with an advanced stage of breast cancer.
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The c-kit proto-oncogene encodes a transmembrane tyrosine
kinase receptor, sharing a structural similarity with the platelet-
derived growth factor and colony-stimulating factor-1 receptor
(Yarden et al, 1987; Qiu et al, 1988). The c-kit is activated by its
ligand, stem cell factor, and plays various roles in haematopoiesis,
melanogenesis, spermatogenesis and the development of the inter-
stitial cells of Cajal (Ronnstrand, 2004). The c-kit is physiologically
expressed in haematopoietic stem cells, tissue mast cells, germ
cells, melanocytes, interstitial cells of Cajal and mammary gland
epithelium, whereas the c-kit is not usually expressed in the
normal squamous epithelium and the glandular epithelium of the
lung, endocervix, pancreas, prostate, stomach and small and large
intestines (Matsuda et al, 1993; Lammie et al, 1994). The diverse
expressions of the c-kit in the normal tissues result in the diverse
expressions of the c-kit in the tumour tissue originated from such
normal tissues (Matsuda et al, 1993; Lammie et al, 1994; Gibson
and Cooper, 2002). There have been several studies regarding the
c-kit expression of breast cancer, indicating that the c-kit
expression decreased in breast cancer tissue whereas the normal
epithelium of the mammary gland showed the c-kit expression
(Natali et al, 1992a; Matsuda et al, 1993; Hines et al, 1995; Chui
et al, 1996; Palmu et al, 2002; Tsuura et al, 2002; Ko et al, 2003;
Simon et al, 2004; Ulivi et al, 2004; Yared et al, 2004). There have,
however, so far been few studies on the relationship between the
c-kit expression of breast cancer and clinicolpathological factor
such as lymph node metastasis and the proliferative activity, and
the prognostic value of the c-kit expression in breast cancer has
not yet been evaluated. Therefore, the aim of the present study
was to evaluate the relationship between the c-kit expression and
the clinicopathological factors in invasive ductal carcinoma of
the breast, and the prognostic value of the c-kit expression in
breast cancer was also evaluated using univariate and multivariate
analyses.
PATIENTS AND METHODS
Patients
This study comprised 217 women with breast cancer who
underwent surgery for breast cancer, without any evidence of
distant metastasis at the time of surgery, between 1985 and 1998 at
the Beppu Medical Center. The histological type of breast cancer in
all patients was invasive ductal carcinoma, while any types other
than invasive ductal carcinoma were excluded in this study. No
cases of noninvasive carcinoma were included in this study. The
patients’ ages ranged from 23 to 86 years, with a mean age of
57.0 years. The patients were either treated by a mastectomy
(186 patients) or by breast conservation treatment (31 patients).
Lymph nodes dissection was performed in 216 patients. Adjuvant
postoperative hormone therapy was given to 190 patients and
190 patients received adjuvant chemotherapy, while 46 patients
received postoperative radiotherapy. The median follow-up dura-
tion was 6.59 years.
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For an immunohistochemical analysis of the c-kit protein, 3-ı `m
sections were dewaxed and rehydrated, and antigen retrieval was
performed by microwave heating for 15min in a 10mM citrate
buffer at pH 6.0. Next, the sections were reacted with rabbit
polyclonal antibody for c-kit (A4502, DAKO, Kyoto, Japan) diluted
at 1:100 for 60min at room temperature, and then were
subsequently stained by the universal immuno-peroxidase
polymer method using a Histofine Simple Stain MAX PO(M) kit
(Nichirei Corp., Tokyo, Japan), according to the protocol provi-
ded by the manufacturer. Positive reactions were visualised with
diaminobenzidine, followed by counterstaining with haematoxylin.
A normal mammary gland was used as an internal control for
c-kit protein expression in the present study, since the normal
mammary gland was demonstrated to show the c-kit protein
expression (Natali et al, 1992a; Tsuura et al, 2002; Ulivi et al, 2004;
Yared et al, 2004). Any slides in which there was no normal
mammary gland or slides in which a normal mammary gland
did not express an adequate degree of immunohistochemical
staining of the c-kit protein were excluded in the present study.
The immunohistochemical expression of breast cancer cells
was judged to demonstrate either a positive or negative expression,
in comparison to the c-kit protein expression of the normal
mammary gland (Figure 1). The c-kit protein expression was
independently determined by three authors (ST, KY and SE) in
whom two authors did not know any clinicopathological informa-
tion for each patient.
We also examined any correlations between the c-kit expression
and other biological parameters for cell cycle regulation (p53
protein) and cell proliferation (MIB-1 counts) that have been
previously studied by immunohistochemistry for the tumours in
the present series (Tsutsui et al, 2004). The immunohistochemical
procedures and results for these parameters have all been
described previously (Tsutsui et al, 2004).
Figure 1 Immunohistochemical expression of c-kit protein in breast cancer. Two cases with a positive expression of the c-kit protein in breast cancer cells
(A and B). A case with a negative expression of c-kit protein (C: normal mammary gland and D: breast cancer cells in the same slide), in which the
expression of c-kit protein of breast cancer cells (D) was negative, in comparison to the expression of the c-kit protein in the normal mammary gland (C).
Table 1 The c-kit expression and clinicopathological factors in breast
cancer
c-kit expression
Negative Positive
No. of
patients n¼158 (%) n¼59 (%) P-value
Age 0.3807
o50 71 49 (69) 22 (31)
50p 146 109 (75) 37 (25)
Tumour size (cm) 0.1532
–2.0 54 34 (63) 20 (37)
2.1–5.0 138 104 (75) 34 (25)
5.1– 25 20 (80) 5 (20)
Lymph node
metastasis
a
o0.0001
Absent 117 72 (62) 45 (38)
Present 99 85 (86) 14 (14)
Nuclear grade 0.1188
I or II 148 103 (70) 45 (30)
III 69 55 (80) 14 (20)
Oestrogen receptor 0.6139
Positive 86 61 (71) 25 (29)
Negative 131 97 (74) 34 (26)
MIB-1 counts 0.4333
Negative (o10%) 127 95 (75) 32 (25)
Positive (10%p) 90 63 (70) 27 (30)
P53 protein expression 0.6025
Negative 160 118 (74) 42 (26)
Positive 57 40 (70) 17 (30)
aLymph node dissection was performed in 216 patients.
c-kit in breast cancer
S Tsutsui et al
1875
British Journal of Cancer (2006) 94(12), 1874–1878 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sStatistical analysis
The w
2 test was used to investigate the significance of the rela-
tionships between the c-kit expression and individual variables.
The disease-free survival (DFS) was estimated using the Kaplan
and Meier method, and any differences in the survival curves were
compared by the Log-rank test. A multivariate analysis was
performed by Cox’s proportional hazards model. The P-value of
o0.05 was regarded as statistically significant. All statistical
analyses were performed using the StatView 5.0 software package
(SAS institute Inc. Cary, NC, USA).
RESULTS
The immunohistochemical expression of the c-kit protein of breast
cancer was determined to be positive in 59 (27%) of 217 tumours,
while the c-kit expression was negative in 158 (73%) of 217
tumours. The relationships between the c-kit expression and
clinicopathological factors in the 217 breast cancers are shown in
Table 1. There was a significant correlation between a negative
expression of the c-kit protein and lymph node metastasis
(Po0.0001), while the c-kit expression did not significantly
correlate with tumour size, nuclear grade, oestrogen receptor
status, MIB-1 counts, and p53 protein expression. Table 2 shows
the relationship between the c-kit expression and the number of
the metastatic lymph nodes. The incidence of a negative expression
of the c-kit protein increased as the number of the metastatic
lymph nodes increased (P¼0.0003).
A univariate analysis indicated the 158 patients with a negative
c-kit expression to have a significantly (P¼0.0041) worse DFS
than the 59 patients with a positive c-kit expression (Figure 2). In
the 117 patients negative for lymph node metastasis, no significant
difference was observed in the DFS of the patients between a
positive and negative c-kit expression. A multivariate analysis
determined lymph node metastasis and the MIB-1 counts to be
independently significant factors for DFS, while the c-kit expres-
sion was not an independently significant (P¼0.3108) factor for
DFS (Table 3).
DISCUSSION
Gastrointestinal stromal tumour (GIST) was demonstrated to be
frequently associated with mutations in the c-kit gene and an
activating mutation in exon 11 of the c-kit gene is considered to be
a causative factor for GIST (Hirota et al, 1998). On the other hand,
no activating mutation of c-kit was found in breast cancer (Simon
et al, 2004) and c-kit is physiologically expressed in the normal
gland of the breast (Natali et al, 1992a; Tsuura et al, 2002; Ulivi
et al, 2004; Yared et al, 2004). In the present study, a normal
mammary gland in the same slide was therefore used as an internal
control for the immunohistochemical expression of c-kit protein,
while a loss of the c-kit protein expression of the cancer cells was
determined in comparison with the c-kit protein expression
of normal mammary glands. Similar findings, indicating that
c-kit is involved in the growth and maintenance of the normal
epithelium and the c-kit function may be lost following malignant
transformation (Natali et al, 1992a; Matsuda et al, 1993), have
also been demonstrated in melanoma (Natali et al, 1992b)
and thyroid (Natali et al, 1995) and renal (Miliaras et al, 2004)
cancers.
The published series of studies regarding c-kit expression in
the breast are summarised in Table 4. The rate of a positive
c-kit expression in breast cancer varies from 1 to 82%, which is
likely attributable to the different methods for determining the
c-kit expression. The rate of a positive c-kit expression in the
normal breast tissue was all 100% in four studies (Natali et al,
1992a; Tsuura et al, 2002; Ulivi et al, 2004; Yared et al, 2004).
Table 2 The c-kit expression and the number of the metastatic lymph
nodes in breast cancer
c-kit expression
Negative Positive
No. of the
metastatic
lymph nodes
No. of
patients n¼157 (%) n¼59 (%) P-value
0.0003
0 117 72 (62) 45 (38)
1–3 60 48 (80) 12 (20)
4–9 16 15 (94) 1 (6)
10– 23 22 (96) 1 (4)
Positive c-kit expression
Negative c-kit expression
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Figure 2 Disease free survival curve stratified according to the c-kit
expression.
Table 3 Multivariate analyses for DFS
Variables P-value Relative risk 95% CI
Age
50p (vs o50) 0.4498 0.82 0.48–1.38
Tumour size (cm)
2.1–5.0 (vs  2.0) 0.8303 0.92 0.42–2.01
5.1–(vs  2.0) 0.1458 1.99 0.79–5.05
Lymph node metastasis
Present (vs absent) o0.0001 5.94 2.95–12.0
Nuclear grade
III (vs I or II) 0.0732 1.65 0.95–2.85
Oestrogen receptor
Negative (vs positive) 0.6538 1.14 0.65–1.99
MIB-1 counts
10%p (vs o10%) 0.0142 2.02 1.15–3.53
P53 protein expression
Positive (vs negative) 0.2028 1.50 0.80–2.79
c-kit expression
Negative (vs positive) 0.3108 1.51 0.68–3.33
c-kit in breast cancer
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different studies, the rate of a positive c-kit expression of
benign tumours was always lower than that of normal breast
tissue and the rate of a positive c-kit expression of the breast
cancer was always lower than that of benign tumours in each study
(Natali et al, 1992a; Tsuura et al, 2002; Yared et al, 2004). In two
studies in which the scoring method was used for the immuno-
histochemical staining (Chui et al, 1996; Ko et al, 2003), the
immunoreactive score (IRS) of the c-kit expression of benign
tumours was lower than that of normal breast tissue and the IRS of
the breast cancer was significantly lower than that of the benign
tumours. The finding of the c-kit expression of breast cancer is
quite a contrast to the finding of EGFR and erbB2 expression of
breast cancer, in which the overexpression of EGFR and erbB2
indicated a malignant phenotype of breast cancer (Tsutsui et al,
2002a,b).
The survival analyses for the c-kit expression have been
demonstrated in several malignant tumours (Tonary et al, 2000;
Bar-Sela et al, 2003; Scobie et al, 2003; Krams et al, 2004; Simon
et al, 2004; Pan et al, 2005), while there was only one survival
analysis (Simon et al, 2004) regarding breast cancer, in which no
difference was found in the survival between the patients with or
without the c-kit expression. Although no statistically significant
difference in clinical outcomes has been found in endometrial
adenocarcinomas (Scobie et al, 2003), nasopharygeal carcinomas
(Bar-Sela et al, 2003) and small cell carcinomas of the urinary
bladder (Pan et al, 2005), two studies on ovarian cancers (Tonary
et al, 2000) and neuroblastomas (Krams et al, 2004) indicated an
association between a loss of the c-kit expression and poor
prognosis. In ovarian cancers, the loss of c-kit expression was
associated with a poor prognosis, while the c-kit expression tended
to decrease at an advanced stage (Tonary et al, 2000), being similar
with our findings in breast cancers. On the other hand, the
prognostic value of the c-kit expression was demonstrated based
on multivariate analyses for nueroblastomas (Krams et al, 2004).
In the present study, a univariate analysis demonstrated the
prognosis of the patients with a loss of the c-kit expression to be
significantly worse than those with a positive c-kit expression,
while a multivariate analysis demonstrated lymph node metastasis
and a proliferative activity determined by MIB-1 counts, but not
the c-kit expression, to be independently significant prognostic
factors for DFS. There was a close correlation between a loss of the
c-kit expression and lymph node metastasis in the present study,
while no significant correlation between the c-kit expression and
lymph node metastasis was found in other studies (Chui et al,
1996; Simon et al, 2004; Ulivi et al, 2004). In the present study, the
c-kit expression did not correlate with the MIB-1 counts. The
findings in the present study indicated that a loss of the c-kit
expression was associated with an advanced stage of breast cancer,
but not with a proliferative activity of the cancer cells, and also
suggested that a close correlation between a loss of the c-kit
expression and an advanced stage of breast cancer seems to mainly
account for the prognostic implications of the c-kit expression in
breast cancer.
In conclusion, we demonstrated a loss of c-kit expression, as
demonstrated by immunohistochemistry, to occur in about three-
fourths of all breast cancers. A loss of the c-kit expression
correlated with lymph node metastasis and the incidence in the
loss of the c-kit expression increased as a number of metastatic
lymph nodes increased. The prognostic value of the c-kit
expression was demonstrated by a univariate analysis, but not by
a multivariate analysis. The prognostic implications of the c-kit
expression therefore seem to be due that a loss of the c-kit
expression is associated with an advanced stage of breast
cancer.
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Table 4 Publised series regarding the c-kit expression for breast tissue
c-kit expression
Author (year) Method
Normal breast
tissue Benign tumours In situ cancers
Invasive primary
cancers
Metastatic breast
cancers
Natali et al (1992a,b) IHC
a 6/6 (100%) 28/36 (78%) 10/80 (13%) 1/40 (3%)
Matsuda et al (1993) IHC 2/10 (20%)
Hines et al (1995) mRNA IHC 9/11 (82%)
Chui et al (1996) IHC (IRS
b) 6.22+2.11 (n¼20) 3.33+2.44 (n¼58) 0.43+1.27 (n¼57)
Tsuura et al (2002) IHC 338/338 (100%) 131/141 (93%) 0/11 (0%) 2/171 (1%)
Palmu et al (2002) IHC 33/40
c (82%)
Ko et al (2003) IHC (IRS) 5.90+1.37 (n¼20) 4.05+1.82 (n¼20) 0.90+1.79 (n¼40) 1.06+1.86
d (n¼18)
0.20+0.63
e (n¼10)
Yared et al (2004) IHC 21/21 (100%) 16/24 (88%) 3/29 (10%) 4/41 (10%) 0/4 (0%)
Ulivi et al (2004) IHC 14/14 (100%) 7/16 (44%) 7/75 (9%)
mRNA 14/14 (100%) 12/16 (75%) 3/14 (21%)
Simon et al (2004) IHC 43/1654 (2.6%)
aImuunohistochemistry.
bImmunoreactive score.
cAll patients have progressive metastatic breast cancer.
dAverage in the metastatic lymph nodes.
eAverage in distant metastases.
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